



**COLORADO**

Department of Health Care  
Policy & Financing

## AGENDA

### Pharmaceuticals & Therapeutics Committee

### Department of Health Care Policy & Financing

Zoom Webinar Registration:

[https://us02web.zoom.us/webinar/register/WN\\_KFzbWoWMQ1KHJt-KcFlmEw](https://us02web.zoom.us/webinar/register/WN_KFzbWoWMQ1KHJt-KcFlmEw)

Tuesday, January 09, 2024, 1:00-5:00 P.M.

#### 1. Committee Member Introductions

Introduction of New Members

Vote for Committee Positions - Chairperson, Vice Chairperson

#### 2. Unfinished Business and General Orders

Approval of minutes from October 3, 2023 P&T meeting

Updates from October 3, 2023 P&T Meeting

#### 3. New Business

Updates from the Prior Authorization Call Center

#### 4. Drug Classes Up for Review

Review of Non-Opioid Analgesia Agents - Oral & Topical - *Removed from Mass Review*

Review of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral - *Removed from Mass Review*

Review of Opioids - Short-Acting, Fentanyl Preparations, Long-Acting

Review of Anticonvulsants, Oral

Review of Newer Generation Antidepressants

Review of Atypical Antipsychotics - Oral/Topical - *Removed from Mass Review*

Review of Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)

Review of Sedative Hypnotics

Review of Skeletal Muscle Relaxants

Review of Stimulants and Related Agents - *Removed from Mass Review*

Review of Diabetes Management Classes - Insulins- Rapid, Short, Intermediate, Long-Acting, Mixtures, Concentrated

Review of Multiple Sclerosis Therapies - Disease Modifying & Symptom Management

Review of Ophthalmics, Immunomodulators

Review of Ophthalmics, Anti-Inflammatories - *Removed from Mass Review*

Review of Ophthalmics, Glaucoma- *Removed from Mass Review*

Mass review drug classes:

- Monoamine Oxidase Inhibitors (MAOIs)

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



- Tricyclic Antidepressants (TCAs)
- Anti-Parkinson's Agents
- Benzodiazepines (Non-Sedative Hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Lithium Agents
- Neurocognitive Disorder Agents
- Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
- Ophthalmics, Allergy

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, [jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com) and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, [greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **January 2nd, 2024 by 5pm MST**.

## 5. Adjourn

Upcoming Meeting Date: April 9, 2024.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

